CD80 and neoplasm: In line with these findings, we showed that STAT3-deficient neutrophils increase their expression of MHCII, CD80/86, and ICAM-1 and operate by licensing antitumoral cytotoxic CD8+ T cell responses rather than by direct killing of tumor cells.